Literature DB >> 29766398

Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.

Marianna Mavilia1, Agnes McAuliffe2, Safina Hafeez3, Haleh Vaziri4.   

Abstract

Hepatosplenic T cell lymphoma (HSTCL) is a rare subtype of peripheral non-Hodgkin lymphoma, of which 20% of cases are associated with chronic immunosuppression. It often occurs in patients with inflammatory bowel disease treated with immunomodulating medications such a thiopurines or TNF-alpha inhibitors. Cytopenias are commonly seen but autoimmune hemolytic anemia (AIHA) is rare. Here we present a young male with longstanding ulcerative colitis on chronic azathioprine, exhibiting several rare features of HSTCL. He initially presented with refractory AIHA, thrombocytopenia, and massive splenomegaly, requiring splenectomy. Histologic examination of his spleen confirmed diagnosis of HSTCL. Approximately 3 months after diagnosis, he was found to have leukemic transformation, representing a secondary malignancy.

Entities:  

Keywords:  Autoimmune hemolytic anemia; Inflammatory bowel disease; Lymphoma; TNF alpha inhibitor; Thiopurines

Mesh:

Substances:

Year:  2018        PMID: 29766398     DOI: 10.1007/s12328-018-0869-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  27 in total

1.  Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy.

Authors:  Armin Rashidi; Michael E Lee; Stephen I Fisher
Journal:  Int J Hematol       Date:  2012-04-22       Impact factor: 2.490

Review 2.  Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

Authors:  Anne Thai; Thomas Prindiville
Journal:  J Crohns Colitis       Date:  2010-06-25       Impact factor: 9.071

3.  Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.

Authors:  Sandra Bašić Kinda; Nadira Duraković; Snježana Dotlić; Ranka Serventi Seiwerth; Sanja Davidović Mrsić; Klara Dubravčić; Igor Aurer
Journal:  Leuk Lymphoma       Date:  2012-11-26

4.  Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.

Authors:  Deepak Parakkal; Humberto Sifuentes; Rumi Semer; Eli Daniel Ehrenpreis
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

5.  Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia.

Authors:  R Lai; L M Larratt; W Etches; S T Mortimer; L D Jewell; L Dabbagh; R W Coupland
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

6.  A Case of a Young Woman with Hepatosplenic gamadelta T-cell Lymphoma.

Authors:  I G Park; C W Suh; J R Hur; S J Kim; K U Park; S J Park; D D Seo; M S Ahn; G D Jang; W K Kim
Journal:  Cancer Res Treat       Date:  2001-06       Impact factor: 4.679

7.  Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease.

Authors:  Michael Montgomery; Marije M van Santen; Bart J Biemond; Robert H Diamond; Steven T Pals
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

8.  Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation.

Authors:  S Mastovich; H Ratech; R E Ware; J O Moore; M J Borowitz
Journal:  Hum Pathol       Date:  1994-01       Impact factor: 3.466

9.  An Unusual Case of Hepatosplenic αβ T-Cell Lymphoma Presenting with Coombs'-Negative Hemolytic Anemia.

Authors:  Feryal A Ibrahim; Vignesh Shanmugam; Aliaa Amer; Halima El-Omri; Ahmad Al-Sabbagh; Ruba Y Taha; Dina S Soliman
Journal:  Clin Med Insights Oncol       Date:  2015-12-02

10.  Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Authors:  Saranya A Selvaraj; Elizabeth Chairez; Lisa M Wilson; Mark Lazarev; Eric B Bass; Susan Hutfless
Journal:  Syst Rev       Date:  2013-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.